Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
scFv-FrC
- Development stage
- Unknown
- Lead developer
- University of Southampton
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intramuscular
01
Overview
scFv-FrC is a patient-specific DNA fusion vaccine designed for the treatment of multiple myeloma. It encodes a fusion protein comprising a tumor-derived single chain variable fragment (scFv), which represents the tumor-specific idiotype (Id), linked to fragment C (FrC) of tetanus toxin. The vaccine aims to induce Id-specific T-cell and antibody responses, with FrC serving as an immune alert signal to enhance the overall immunological response against the myeloma cells. It was developed by researchers at the University of Southampton and University of Bristol.
02
Targets
Id (Tumor-specific idiotype immunoglobulin)
Beyond the preview
Go deeper on scFv-FrC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on scFv-FrC.